Athol U Wells

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8190501/publications.pdf

Version: 2024-02-01

447 papers	54,840 citations	1461 110 h-index	1719 219 g-index
454 all docs	454 docs citations	454 times ranked	27622 citing authors

#	Article	IF	Citations
1	Assessment of dyspnea in sarcoidosis using the Baseline Dyspnea Index (BDI) and the Transition Dyspnea Index (TDI). Respiratory Medicine, 2022, 191, 106436.	1.3	9
2	Detection and Early Referral of Patients With Interstitial Lung Abnormalities. Chest, 2022, 161, 470-482.	0.4	26
3	General Principles of ILD: Diagnosis and Management. , 2022, , 1-9.		0
4	Impact of Lung Biopsy Information on Treatment Strategy of Patients with Interstitial Lung Diseases. Annals of the American Thoracic Society, 2022, 19, 737-745.	1.5	9
5	Shortâ€term lung function changes predict mortality in patients with fibrotic hypersensitivity pneumonitis. Respirology, 2022, 27, 202-208.	1.3	11
6	The role of precision medicine in interstitial lung disease. European Respiratory Journal, 2022, 60, 2102146.	3.1	13
7	WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension. European Respiratory Review, 2022, 31, 210165.	3.0	28
8	Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases. Respirology, 2022, 27, 294-300.	1.3	15
9	Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 247-259.	2.5	15
10	CYFRA 21-1 Predicts Progression in Idiopathic Pulmonary Fibrosis: A Prospective Longitudinal Analysis of the PROFILE Cohort. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1440-1448.	2.5	14
11	The six-minute walk test in sarcoidosis associated pulmonary hypertension: Results from an international registry. Respiratory Medicine, 2022, 196, 106801.	1.3	15
12	Incidental discovery of interstitial lung disease: diagnostic approach, surveillance and perspectives. European Respiratory Review, 2022, 31, 210206.	3.0	15
13	World Association for Sarcoidosis and Other Granulomatous Disease (WASOG) Centers of Excellence.. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2022, 38, e2021051.	0.2	0
14	Interstitial Lung Abnormalities: An Evolving Entity. American Journal of Respiratory and Critical Care Medicine, 2022, , .	2.5	0
15	Lung cancer in patients with fibrosing interstitial lung diseases: an overview of current knowledge and challenges. ERJ Open Research, 2022, 8, 00115-2022.	1.1	13
16	Analyses of the Efficacy and Safety of Antifibrotic Therapies in Non-IPF Pulmonary Fibrosis, Progressing Despite Management. Annals of the American Thoracic Society, 2022, 19, 904-906.	1.5	0
17	Integration and Application of Clinical Practice Guidelines for the Diagnosis of Idiopathic Pulmonary Fibrosis and Fibrotic Hypersensitivity Pneumonitis. Chest, 2022, 162, 614-629.	0.4	19
18	Deep Learningâ€"based Outcome Prediction in Progressive Fibrotic Lung Disease Using High-Resolution Computed Tomography. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 883-891.	2.5	29

#	Article	IF	Citations
19	STRATUS: A Phase II Study of Abituzumab in Patients With Systemic Sclerosisâ€“associated Interstitial Lung Disease. Journal of Rheumatology, 2021, 48, 1295-1298.	1.0	12
20	The Respiratory Microbiome in Chronic Hypersensitivity Pneumonitis Is Distinct from That of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 339-347.	2.5	45
21	Pharmacological management of Idiopathic Pulmonary Fibrosis: current and emerging options. Expert Opinion on Pharmacotherapy, 2021, 22, 191-204.	0.9	16
22	BTS Clinical Statement on pulmonary sarcoidosis. Thorax, 2021, 76, 4-20.	2.7	90
23	The DIAMORFOSIS (DIAgnosis and Management Of lung canceR and FibrOSIS) survey: international survey and call for consensus. ERJ Open Research, 2021, 7, 00529-2020.	1.1	22
24	Serum markers of pulmonary epithelial damage in systemic sclerosisâ€associated interstitial lung disease and disease progression. Respirology, 2021, 26, 461-468.	1.3	30
25	Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respiratory Medicine,the, 2021, 9, 85-95.	5.2	96
26	BAL Is Safe and Well Tolerated in Individuals with Idiopathic Pulmonary Fibrosis: An Analysis of the PROFILE Study. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 136-139.	2.5	15
27	New insights into the treatment of CTD-ILD. Nature Reviews Rheumatology, 2021, 17, 79-80.	3.5	14
28	Covid-19 Interstitial Pneumonia: Histological and Immunohistochemical Features on Cryobiopsies. Respiration, 2021, 100, 488-498.	1.2	75
29	Chest radiography or computed tomography for COVID-19 pneumonia? Comparative study in a simulated triage setting. European Respiratory Journal, 2021, 58, 2004188.	3.1	47
30	Reply to Althuwaybi et al.: Hospitalization Outcomes for COVID-19 in Patients with Interstitial Lung Disease: A Potential Role for Aerodigestive Pathophysiology?. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 522-524.	2.5	0
31	Interstitial Lung Disease after COVID-19 Infection: A Catalog of Uncertainties. Radiology, 2021, 299, E216-E218.	3.6	54
32	A case series on the use of steroids and mycophenolate mofetil in idiopathic and heritable pulmonary veno-occlusive disease: is there a role for immunosuppression?. European Respiratory Journal, 2021, 57, 2004354.	3.1	9
33	P157â€ƒPotential benefit of intravenous immunoglobulin in connective tissue disease associated interstitial lung diseases. Rheumatology, 2021, 60, .	0.9	0
34	Pirfenidone in patients with non-IPF progressive fibrotic interstitial lung diseases: expert guidance is urgently needed. Lancet Respiratory Medicine,the, 2021, 9, 437-438.	5.2	5
35	Inhaled trepostinil for severe fibrotic interstitial lung disease: grounds for cautious optimism?. Lancet Respiratory Medicine,the, 2021, 9, 1209-1211.	5.2	5
36	Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE-IIP study. Journal of Heart and Lung Transplantation, 2021, 40, 494-503.	0.3	20

#	Article	IF	Citations
37	ERS clinical practice guidelines on treatment of sarcoidosis. European Respiratory Journal, 2021, 58, 2004079.	3.1	248
38	Muscle stimulation in advanced idiopathic pulmonary fibrosis: a randomised placebo-controlled feasibility study. BMJ Open, 2021, 11, e048808.	0.8	7
39	The progressive fibrotic phenotype in current clinical practice. Current Opinion in Pulmonary Medicine, 2021, 27, 368-373.	1.2	7
40	Pulmonary vascular involvement in <scp>COVID</scp>â€19 pneumonitis: Is this the first and final insult?. Respirology, 2021, 26, 832-834.	1.3	6
41	Residual Lung Disease at Six-month Follow-up CT after COVID-19: Clinical Significance Is a Key Issue. Radiology, 2021, 301, E406-E408.	3.6	8
42	Mortality in combined pulmonary fibrosis and emphysema patients is determined by the sum of pulmonary fibrosis and emphysema. ERJ Open Research, 2021, 7, 00316-2021.	1.1	6
43	Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process. Seminars in Arthritis and Rheumatism, 2021, , .	1.6	3
44	Diagnosis and Evaluation of Hypersensitivity Pneumonitis. Chest, 2021, 160, e97-e156.	0.4	104
45	Pleuroparenchymal fibroelastosis in idiopathic pulmonary fibrosis: Survival analysis using visual and computer-based computed tomography assessment. EClinicalMedicine, 2021, 38, 101009.	3.2	6
46	An IPF-like disease course in disorders other than IPF: how can this be anticipated, recognized, and managed?. Expert Review of Clinical Immunology, 2021, 17, 1091-1101.	1.3	4
47	Transbronchial Cryobiopsy in Interstitial Lung Diseases. Journal of Bronchology and Interventional Pulmonology, 2021, 28, 81-92.	0.8	10
48	Pharmacological and nonpharmacological interventions to improve symptom control, functional exercise capacity and quality of life in interstitial lung disease: an evidence synthesis. ERJ Open Research, 2021, 7, 00107-2020.	1.1	4
49	Collagen 1a1 Expression by Airway Macrophages Increases In Fibrotic ILDs and Is Associated With FVC Decline and Increased Mortality. Frontiers in Immunology, 2021, 12, 645548.	2.2	17
50	Bronchoalveolar lavage and lung biopsy in connective tissue diseases, to do or not to do?. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110596.	1.2	14
51	Interstitial pneumonia with autoimmune features: challenges and controversies. European Respiratory Review, 2021, 30, 210177.	3.0	16
52	Right Ventricular to Left Ventricular Ratio atÂCT Pulmonary Angiogram Predicts Mortality in Interstitial Lung Disease. Chest, 2020, 157, 89-98.	0.4	30
53	Pamrevlumab in idiopathic pulmonary fibrosis. Lancet Respiratory Medicine,the, 2020, 8, 2-3.	5.2	14
54	Risk factors for disease progression in idiopathic pulmonary fibrosis. Thorax, 2020, 75, 78-80.	2.7	22

#	Article	IF	Citations
55	Physiological predictors of exertional oxygen desaturation in patients with fibrotic interstitial lung disease. European Respiratory Journal, 2020, 55, 1901681.	3.1	11
56	Cost-effectiveness of ambulatory oxygen in improving quality of life in fibrotic lung disease: preliminary evidence from the AmbOx Trial. European Respiratory Journal, 2020, 55, 1901157.	3.1	7
57	Defining genetic risk factors for scleroderma-associated interstitial lung disease. Clinical Rheumatology, 2020, 39, 1173-1179.	1.0	12
58	Transbronchial Cryobiopsy for the Diagnosis of Interstitial Lung Diseases. Chest, 2020, 157, 1030-1042.	0.4	134
59	Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1656-1665.	2.5	171
60	Prognostic value of transbronchial lung cryobiopsy for the multidisciplinary diagnosis of idiopathic pulmonary fibrosis: a retrospective validation study. Lancet Respiratory Medicine,the, 2020, 8, 786-794.	5.2	38
61	COVIDâ€19 related lung pathology: old patterns in new clothing?. Histopathology, 2020, 77, 169-172.	1.6	24
62	Transbronchial cryobiopsy increases diagnostic confidence in interstitial lung disease: a prospective multicentre trial. European Respiratory Journal, 2020, 56, 1901520.	3.1	41
63	Serial CT analysis in idiopathic pulmonary fibrosis: comparison of visual features that determine patient outcome. Thorax, 2020, 75, 648-654.	2.7	26
64	Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respiratory Medicine,the, 2020, 8, 807-815.	5.2	802
65	Mixed Ventilatory Defects in Pulmonary Sarcoidosis. Chest, 2020, 158, 2007-2014.	0.4	28
66	Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry. European Respiratory Journal, 2020, 55, 1901747.	3.1	67
67	Contemporary Concise Review 2019: Interstitial lung disease. Respirology, 2020, 25, 756-763.	1.3	2
68	The role of CT in case ascertainment and management of COVID-19 pneumonia in the UK: insights from high-incidence regions. Lancet Respiratory Medicine,the, 2020, 8, 438-440.	5.2	74
69	Nintedanib in patients with progressive fibrosing interstitial lung diseasesâ€"subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respiratory Medicine,the, 2020, 8, 453-460.	5.2	331
70	Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. Lancet Respiratory Medicine,the, 2020, 8, 726-737.	5.2	279
71	Patients with idiopathic pulmonary fibrosis: Overcoming â€˜geographic isolationâ€™. Respirology, 2020, 25, 1019-1020.	1.3	0
72	Interaction between the promoter MUC5B polymorphism and mucin expression: is there a difference according to ILD subtype?. Thorax, 2020, 75, 901-903.	2.7	8

#	Article	IF	Citations
73	Patient gender bias on the diagnosis of idiopathic pulmonary fibrosis. Thorax, 2020, 75, 407-412.	2.7	30
74	Imaging research in fibrotic lung disease; applying deep learning to unsolved problems. Lancet Respiratory Medicine,the, 2020, 8, 1144-1153.	5.2	47
75	Bacterial burden in the lower airways predicts disease progression in idiopathic pulmonary fibrosis and is independent of radiological disease extent. European Respiratory Journal, 2020, 55, 1901519.	3.1	42
76	A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis. Chest, 2020, 157, 1506-1512.	0.4	33
77	Lung Parenchymal and Tracheal CT Morphology: Evaluation before and after Bariatric Surgery. Radiology, 2020, 294, 669-675.	3.6	7
78	When the Game Changes. Chest, 2020, 158, 892-895.	0.4	36
79	The Role of Chest Imaging in Patient Management During the COVID-19 Pandemic. Chest, 2020, 158, 106-116.	0.4	832
80	Pleuroparenchymal fibroelastosis in systemic sclerosis: prevalence and prognostic impact. European Respiratory Journal, 2020, 56, 1902135.	3.1	34
81	The natural history of progressive fibrosing interstitial lung diseases. European Respiratory Journal, 2020, 55, 2000085.	3.1	148
82	Prognostic impact of typical and probable usual interstitial pneumonia pattern in idiopathic pulmonary fibrosis: is the debate about biopsy a Star Wars saga?. European Respiratory Journal, 2020, 55, 2000590.	3.1	2
83	Managing the supportive care needs of those affected by COVID-19. European Respiratory Journal, 2020, 55, 2000815.	3.1	95
84	Computed Tomographic Biomarkers in Idiopathic Pulmonary Fibrosis. The Future of Quantitative Analysis. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 12-21.	2.5	102
85	Diagnostic value of BAL lymphocytosis in patients with indeterminate for usual interstitial pneumonia imaging pattern. European Respiratory Journal, 2019, 54, 1901144.	3.1	27
86	Longitudinal prediction of outcome in idiopathic pulmonary fibrosis using automated CT analysis. European Respiratory Journal, 2019, 54, 1802341.	3.1	22
87	Communication difficulties reported by patients diagnosed with idiopathic pulmonary fibrosis and their carers: a European focus group study. ERJ Open Research, 2019, 5, 00055-2019.	1.1	13
88	Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1146-1153.	2.5	60
89	Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study. Lancet Respiratory Medicine,the, 2019, 7, 780-790.	5.2	139
90	Before Freezing Out Cryobiopsy, We Need to Thaw Out Flaws in the Diagnosis of Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 937-938.	2.5	10

#	Article	IF	Citations
91	Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. New England Journal of Medicine, 2019, 381, 1718-1727.	13.9	1,338
92	Diagnostic yield and risk/benefit analysis of trans-bronchial lung cryobiopsy in diffuse parenchymal lung diseases: a large cohort of 699 patients. BMC Pulmonary Medicine, 2019, 19, 16.	0.8	147
93	Mortality in Sarcoidosis. , 2019, , 305-312.		0
94	Diagnosing complications and co-morbidities of fibrotic interstitial lung disease. Expert Review of Respiratory Medicine, 2019, 13, 645-658.	1.0	12
95	Novel exploratory data in interstitial lung disease. Respirology, 2019, 24, 718-719.	1.3	2
96	Variable utility of mosaic attenuation toÂdistinguish fibrotic hypersensitivity pneumonitis from idiopathic pulmonary fibrosis. European Respiratory Journal, 2019, 54, 1900531.	3.1	52
97	Multidisciplinary Evaluation in Patients with Lung Disease Associated with Connective Tissue Disease. Seminars in Respiratory and Critical Care Medicine, 2019, 40, 184-193.	0.8	25
98	Pulmonary Complications of Connective Tissue Disease. Seminars in Respiratory and Critical Care Medicine, 2019, 40, 145-146.	0.8	2
99	Visual and Automated CT Measurements of Lung Volume Loss in Idiopathic Pulmonary Fibrosis. American Journal of Roentgenology, 2019, 213, 318-324.	1.0	35
100	Bromodomain and Extraterminal (BET) Protein Inhibition Restores Redox Balance and Inhibits Myofibroblast Activation. BioMed Research International, 2019, 2019, 1-11.	0.9	23
101	Clinical trial design for acute exacerbations in idiopathic pulmonary fibrosis: A thorny path. Respirology, 2019, 24, 620-621.	1.3	1
102	Pulmonary fibrosis: â€œidiopathicâ€•is not â€œcryptogenicâ€• European Respiratory Journal, 2019, 53, 1900400.	3.1	1
103	Psychometric properties and minimal important differences of SF-36 in Idiopathic Pulmonary Fibrosis. Respiratory Research, 2019, 20, 47.	1.4	31
104	Lung CT Densitometry in Idiopathic Pulmonary Fibrosis for the Prediction of Natural Course, Severity, and Mortality. Chest, 2019, 155, 972-981.	0.4	32
105	Early histological changes of pulmonary arterial hypertension disclosed by invasive cardiopulmonary exercise testing. Pulmonary Circulation, 2019, 9, 1-4.	0.8	3
106	The Kingâ€™s Brief Interstitial Lung Disease (KBILD) questionnaire: an updated minimal clinically important difference. BMJ Open Respiratory Research, 2019, 6, e000363.	1.2	30
107	In patients with idiopathic pulmonary fibrosis the presence of hiatus hernia isÂassociated with disease progression andÂmortality. European Respiratory Journal, 2019, 53, 1802412.	3.1	20
108	Quantitative CTâ€derived vessel metrics in idiopathic pulmonary fibrosis: A structureâ€“function study. Respirology, 2019, 24, 445-452.	1.3	17

#	Article	IF	Citations
109	Idiopathic interstitial pneumonia or idiopathic interstitial pneumonitis: what'sÂin a name?. European Respiratory Journal, 2019, 53, 1801939.	3.1	6
110	Idiopathic pulmonary fibrosis: prognostic impact of histologic honeycombing in transbronchial lung cryobiopsy. Multidisciplinary Respiratory Medicine, 2019, 14, 3.	0.6	5
111	Interstitial lung diseases: courseÂreport. Breathe, 2019, 15, 270-272.	0.6	0
112	Treatment of cardiac sarcoidosis. Current Opinion in Pulmonary Medicine, 2019, 25, 519-525.	1.2	8
113	Advanced sarcoidosis. Current Opinion in Pulmonary Medicine, 2019, 25, 497-504.	1.2	40
114	Efficacy data in treatment extension studies of idiopathic pulmonary fibrosis: interpret with caution. Lancet Respiratory Medicine,the, 2019, 7, 7-8.	5.2	3
115	Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis. Chest, 2019, 155, 712-719.	0.4	24
116	The potential impact of azithromycin in idiopathic pulmonary fibrosis. European Respiratory Journal, 2019, 53, 1800628.	3.1	32
117	Lung function outcomes in the INPULSISÂ® trials of nintedanib in idiopathic pulmonary fibrosis. Respiratory Medicine, 2019, 146, 42-48.	1.3	34
118	Predicting outcomes in rheumatoid arthritis related interstitial lung disease. European Respiratory Journal, 2019, 53, 1800869.	3.1	121
119	Predicting Outcomes in Idiopathic Pulmonary Fibrosis Using Automated Computed Tomographic Analysis. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 767-776.	2.5	140
120	Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study â€“ Rationale and study design. Respiratory Medicine, 2018, 138, 13-20.	1.3	27
121	Pulmonary sarcoidosis. Lancet Respiratory Medicine,the, 2018, 6, 389-402.	5.2	544
122	Rapidly Progressive Cystic Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 264-264.	2.5	2
123	Diagnostic Ability of a Dynamic Multidisciplinary Discussion in Interstitial Lung Diseases. Chest, 2018, 153, 1416-1423.	0.4	85
124	Idiopathic pulmonary fibrosis: idiopathic no more?. Lancet Respiratory Medicine,the, 2018, 6, 84-85.	5.2	8
125	Validation of multidisciplinary diagnosis in IPF. Lancet Respiratory Medicine,the, 2018, 6, 88-89.	5.2	13
126	Prevalence and Effects of Emphysema in Never-Smokers with Rheumatoid Arthritis Interstitial Lung Disease. EBioMedicine, 2018, 28, 303-310.	2.7	51

#	Article	IF	Citations
127	Disease staging and sub setting of interstitial lung disease associated with systemic sclerosis: impact on therapy. Expert Review of Clinical Immunology, 2018, 14, 127-135.	1.3	8
128	Pulmonary hypertension in interstitial lung disease: Limitations of echocardiography compared to cardiac catheterization. Respirology, 2018, 23, 687-694.	1.3	39
129	Transbronchial Cryobiopsies for the Diagnosis of Diffuse Parenchymal Lung Diseases: Expert Statement from the Cryobiopsy Working Group on Safety and Utility and a Call for Standardization of the Procedure. Respiration, 2018, 95, 188-200.	1.2	273
130	Functional associations of pleuroparenchymal fibroelastosis and emphysema with hypersensitivity pneumonitis. Respiratory Medicine, 2018, 138, 95-101.	1.3	52
131	Treatment doses in idiopathic pulmonary fibrosis: The devil is in the detail. Respirology, 2018, 23, 244-245.	1.3	3
132	Serial automated quantitative CT analysis in idiopathic pulmonary fibrosis: functional correlations and comparison with changes in visual CT scores. European Radiology, 2018, 28, 1318-1327.	2.3	61
133	Likelihood of pulmonary hypertension in patients with idiopathic pulmonary fibrosis and emphysema. Respirology, 2018, 23, 593-599.	1.3	29
134	Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respiratory Medicine,the, 2018, 6, 138-153.	5.2	739
135	Psychometric validation of the needs assessment tool: progressive disease in interstitial lung disease. Thorax, 2018, 73, 880-883.	2.7	15
136	Variable radiological lung nodule evaluation leads to divergent management recommendations. European Respiratory Journal, 2018, 52, 1801359.	3.1	32
137	Pirfenidone improves survival in IPF: results from a real-life study. BMC Pulmonary Medicine, 2018, 18, 177.	0.8	65
138	Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice. ERJ Open Research, 2018, 4, 00049-2018.	1.1	24
139	Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. European Respiratory Review, 2018, 27, 180076.	3.0	370
140	Sarcoidosis: A benign disease or a culture of neglect?. Respiratory Medicine, 2018, 144, S1-S2.	1.3	15
141	Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2018, 379, 1722-1731.	13.9	207
142	IPF diagnosis: flexibility is a virtue. Lancet Respiratory Medicine,the, 2018, 6, 735-737.	5.2	12
143	Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial. Lancet Respiratory Medicine,the, 2018, 6, 759-770.	5.2	145
144	Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2018, 198, e44-e68.	2.5	2,678

#	Article	IF	Citations
145	What's in a name? That which we call IPF, by any other name would act the same. European Respiratory Journal, 2018, 51, 1800692.	3.1	226
146	Sarcoidosis: is cryobiopsy not cool enough? â€“ Authors' reply. Lancet Respiratory Medicine,the, 2018, 6, e45.	5.2	3
147	A stepwise composite echocardiographic score predicts severe pulmonary hypertension in patients with interstitial lung disease. ERJ Open Research, 2018, 4, 00124-2017.	1.1	16
148	Regarding the â€œEvaluation of patients with fibrotic interstitial lung disease: A Canadian Thoracic Society position statementâ€• Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2018, 2, 182-183.	0.2	0
149	Major lung complications of systemic sclerosis. Nature Reviews Rheumatology, 2018, 14, 511-527.	3.5	60
150	Why do people die from pulmonary sarcoidosis?. Current Opinion in Pulmonary Medicine, 2018, 24, 527-535.	1.2	10
151	The Clinical Significance of Body Weight Loss in Idiopathic Pulmonary Fibrosis Patients. Respiration, 2018, 96, 338-347.	1.2	69
152	Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 78-85.	2.5	147
153	Hostâ€“Microbial Interactions in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1640-1650.	2.5	169
154	Impact of pulmonary vascular volume on mortality in IPF: is it time to reconsider the role of vasculature in disease pathogenesis and progression?. European Respiratory Journal, 2017, 49, 1602524.	3.1	6
155	Comorbidities in interstitial lung diseases. European Respiratory Review, 2017, 26, 160027.	3.0	57
156	Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosis. Respiratory Research, 2017, 18, 29.	1.4	156
157	Pirfenidone for the treatment of idiopathic pulmonary fibrosis. Expert Review of Clinical Pharmacology, 2017, 10, 483-491.	1.3	31
158	Diffuse Pulmonary Ossification in Fibrosing Interstitial Lung Diseases: Prevalence and Associations. Radiology, 2017, 284, 255-263.	3.6	65
159	Shortâ€Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis. Arthritis and Rheumatology, 2017, 69, 1670-1678.	2.9	247
160	A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group Perspective. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1249-1254.	2.5	166
161	Chronic hypersensitivity pneumonitis: identification of key prognostic determinants using automated CT analysis. BMC Pulmonary Medicine, 2017, 17, 81.	0.8	52
162	Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. Trials, 2017, 18, 275.	0.7	121

#	Article	IF	Citations
163	Update in Interstitial Lung Disease 2016. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 132-138.	2.5	7
164	Complementary Role of CMR to Conventional Screening in the Diagnosis and Prognosis of Cardiac Sarcoidosis. JACC: Cardiovascular Imaging, 2017, 10, 1437-1447.	2.3	160
165	Transbronchial Lung Cryobiopsy in Diffuse Parenchymal Lung Disease: Comparison between Biopsy from 1 Segment and Biopsy from 2 Segments - Diagnostic Yield and Complications. Respiration, 2017, 93, 285-292.	1.2	82
166	Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. Lancet Respiratory Medicine,the, 2017, 5, 22-32.	5.2	200
167	N-acetylcysteine for idiopathic pulmonary fibrosis: the door is still openâ€"Authors' reply. Lancet Respiratory Medicine,the, 2017, 5, e3.	5.2	2
168	Mortality prediction in idiopathic pulmonary fibrosis: evaluation of computer-based CT analysis with conventional severity measures. European Respiratory Journal, 2017, 49, 1601011.	3.1	211
169	Rebuttal From Drs Wells andÂKokosi. Chest, 2017, 152, 922-923.	0.4	0
170	POINT: Should BAL Be Routinely Performed in the Diagnostic Evaluation of Idiopathic Pulmonary Fibrosis? Yes. Chest, 2017, 152, 917-919.	0.4	13
171	Palliative care in interstitial lung disease: living well. Lancet Respiratory Medicine,the, 2017, 5, 968-980.	5.2	185
172	Idiopathic pulmonary fibrosis. Nature Reviews Disease Primers, 2017, 3, 17074.	18.1	786
173	Interstitial lung disease points to consider for clinical trials in systemic sclerosis. Rheumatology, 2017, 56, v27-v32.	0.9	23
174	Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international caseâ€"cohort study. European Respiratory Journal, 2017, 50, 1700936.	3.1	75
175	Predicting time to decline in FVC using baseline visual and computer-based CT analysis and baseline functional indices. Clinical Radiology, 2017, 72, S24.	0.5	1
176	Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Respiratory Research, 2017, 4, e000212.	1.2	151
177	A rigid solution to a relapsing problem. Lancet Respiratory Medicine,the, 2017, 5, 760.	5.2	0
178	Pleuroparenchymal Fibroelastosis. American Journal of Surgical Pathology, 2017, 41, 1683-1689.	2.1	57
179	Evaluation of visual and computer-based CT analysis for the identification of functional patterns of obstruction and restriction in hypersensitivity pneumonitis. Respirology, 2017, 22, 1585-1591.	1.3	25
180	Unclassifiable-interstitial lung disease: Outcome prediction using CT and functional indices. Respiratory Medicine, 2017, 130, 43-51.	1.3	44

#	Article	IF	Citations
181	An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study. Lancet Respiratory Medicine,the, 2017, 5, 946-955.	5.2	190
182	The Genomic Detection of Usual Interstitial Pneumonia from Transbronchial Biopsy Tissue: A Dress Rehearsal for the Future?. Annals of the American Thoracic Society, 2017, 14, 1632-1633.	1.5	0
183	Functional and prognostic effects when emphysema complicates idiopathic pulmonary fibrosis. European Respiratory Journal, 2017, 50, 1700379.	3.1	71
184	Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?. Lancet Respiratory Medicine,the, 2017, 5, 591-598.	5.2	71
185	Ambulatory oxygen in fibrotic lung disease (AmbOx): study protocol for a randomised controlled trial. Trials, 2017, 18, 201.	0.7	17
186	Effect of Emphysema Extent on Serial Lung Function in Patients with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1162-1171.	2.5	69
187	A new era in idiopathic interstitial pneumonias: <scp>E</scp>pilogue to a review series. Respirology, 2017, 22, 14-16.	1.3	1
188	Unclassifiable interstitial lung diseases: Clinical characteristics and survival. Respirology, 2017, 22, 494-500.	1.3	58
189	Bronchiectasis in yellow nail syndrome. Respirology, 2017, 22, 101-107.	1.3	29
190	Upregulation of citrullination pathway: From Autoimmune to Idiopathic Lung Fibrosis. Respiratory Research, 2017, 18, 218.	1.4	47
191	Proteomic Analysis of Kveim Reagent Identifies Targets of Cellular Immunity in Sarcoidosis. PLoS ONE, 2017, 12, e0170285.	1.1	41
192	The Adaptation, Face, and Content Validation of a Needs Assessment Tool: Progressive Disease for People with Interstitial Lung Disease. Journal of Palliative Medicine, 2016, 19, 549-555.	0.6	28
193	Brief Report: Antiâ€“Eukaryotic Initiation Factor 2B Autoantibodies Are Associated With Interstitial Lung Disease in Patients With Systemic Sclerosis. Arthritis and Rheumatology, 2016, 68, 2778-2783.	2.9	26
194	Evaluation of computer-based computer tomography stratification against outcome models in connective tissue disease-related interstitial lung disease: a patient outcome study. BMC Medicine, 2016, 14, 190.	2.3	69
195	Subclinical Interstitial Lung Abnormalities: Toward the Early Detection of Idiopathic Pulmonary Fibrosis?. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1445-1446.	2.5	26
196	Nonspecific interstitial pneumonia. Current Opinion in Pulmonary Medicine, 2016, 22, 450-455.	1.2	9
197	Nintedanib Reduces Disease Progression in Patients With Idiopathic Pulmonary Fibrosis Irrespective of Composite Physiologic Index at Baseline in the INPULSIS Trials. Chest, 2016, 150, 539A.	0.4	0
198	Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax, 2016, 71, 429-435.	2.7	151

#	Article	IF	Citations
199	Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: a case-cohort study. Lancet Respiratory Medicine,the, 2016, 4, 557-565.	5.2	337
200	Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respiratory Medicine,the, 2016, 4, 445-453.	5.2	108
201	Medical Therapy in Idiopathic Pulmonary Fibrosis. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 368-377.	0.8	20
202	Daily Home Spirometry: An Effective Tool for Detecting Progression in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 989-997.	2.5	138
203	Epigenetic regulation of cyclooxygenase-2 by methylation of c8orf4Âin pulmonary fibrosis. Clinical Science, 2016, 130, 575-586.	1.8	64
204	Computer based CT scoring versus visual CT scores: identifying optimal predictors of functional decline and mortality in IPF. Clinical Radiology, 2016, 71, S26.	0.5	0
205	Rare idiopathic interstitial pneumonias: <scp>LIP</scp> and <scp>PPFE</scp> and rare histologic patterns of interstitial pneumonias: <scp>AFOP</scp> and <scp>BPIP</scp>. Respirology, 2016, 21, 600-614.	1.3	39
206	Accurate diagnosis of cardiac sarcoidosis needs a multidisciplinary approach. British Journal of Hospital Medicine (London, England: 2005), 2016, 77, 614-615.	0.2	8
207	Patient eligibility for anti-fibrotic therapy in idiopathic pulmonary fibrosis can be altered by use of different sets of reference values for calculation of FVC percent predicted. Respiratory Medicine, 2016, 120, 131-133.	1.3	8
208	Automated Quantitative Computed Tomography Versus Visual Computed Tomography Scoring in Idiopathic Pulmonary Fibrosis. Journal of Thoracic Imaging, 2016, 31, 304-311.	0.8	158
209	Pulmonary tumour thrombotic microangiopathy. Current Opinion in Pulmonary Medicine, 2016, 22, 421-428.	1.2	58
210	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. Arthritis Care and Research, 2016, 68, 167-178.	1.5	13
211	Interstitial pneumonitis with autoimmune features (IPAF): a work in progress. European Respiratory Journal, 2016, 47, 1622-1624.	3.1	17
212	â€œAny fool can make a rule and any fool will mind itâ€• BMC Medicine, 2016, 14, 23.	2.3	35
213	Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 265-275.	2.5	1,006
214	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. Arthritis and Rheumatology, 2016, 68, 299-311.	2.9	110
215	Combined Pulmonary Fibrosis and Emphysema in Sclerodermaâ€Related Lung Disease Has a Major Confounding Effect on Lung Physiology and Screening for Pulmonary Hypertension. Arthritis and Rheumatology, 2016, 68, 1004-1012.	2.9	84
216	Broad Therapeutic Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 112-113.	2.5	9

#	Article	IF	Citations
217	Bronchoscopic Lung Cryobiopsy Increases Diagnostic Confidence in the Multidisciplinary Diagnosis of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 745-752.	2.5	292
218	Idiopathic Pulmonary Fibrosis. Chest, 2016, 149, 491-498.	0.4	75
219	Monitoring of Lung Involvement in Rheumatologic Disease. Respiration, 2016, 91, 89-98.	1.2	18
220	Mucins MUC5B and MUC5AC in Distal Airways and Honeycomb Spaces: Comparison among Idiopathic Pulmonary Fibrosis/Usual Interstitial Pneumonia, Fibrotic Nonspecific Interstitial Pneumonitis, and Control Lungs. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 462-464.	2.5	38
221	Sarcoidosis of the cardioâ€“pulmonary systems. Clinical Medicine, 2016, 16, 34-41.	0.8	3
222	Safety and Diagnostic Yield of Transbronchial Lung Cryobiopsy in Diffuse Parenchymal Lung Diseases: A Comparative Study versus Video-Assisted Thoracoscopic Lung Biopsy and a Systematic Review of the Literature. Respiration, 2016, 91, 215-227.	1.2	306
223	Interobserver agreement for the ATS/ERS/JRS/ALAT criteria for a UIP pattern on CT. Thorax, 2016, 71, 45-51.	2.7	256
224	The need to research refractory breathlessness. European Respiratory Journal, 2016, 47, 342-343.	3.1	32
225	MiR-185/AKT and miR-29a/Collagen 1a pathways are activated in IPF BAL cells. Oncotarget, 2016, 7, 74569-74581.	0.8	22
226	Cultural Differences in Palliative Care in Patients With Idiopathic Pulmonary Fibrosis. Chest, 2015, 148, e56.	0.4	13
227	Pirfenidone and N-acetylcysteine (NAC) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF): Exploratory Efficacy Results From the PANORAMA Study. Chest, 2015, 148, 641A.	0.4	1
228	Advances in imaging of cardiopulmonary involvement in sarcoidosis. Current Opinion in Pulmonary Medicine, 2015, 21, 538-545.	1.2	13
229	CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a Position Paper from the Fleischner society. Lancet Respiratory Medicine,the, 2015, 3, 483-496.	5.2	149
230	Relationship between fibroblastic foci profusion and high resolution CT morphology in fibrotic lung disease. BMC Medicine, 2015, 13, 241.	2.3	50
231	Idiopathic interstitial pneumonias in 2015: A new era. Respirology, 2015, 20, 697-698.	1.3	3
232	Pulmonary tumour thrombotic microangiopathy: unclassifiable pulmonary hypertension?. European Respiratory Journal, 2015, 46, 1214-1217.	3.1	38
233	Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosisâ€“associated interstitial lung disease trials. Arthritis Research and Therapy, 2015, 17, 372.	1.6	87
234	Rasch analysis and impact factor methods both yield valid and comparable measures of health status in interstitial lung disease. Journal of Clinical Epidemiology, 2015, 68, 1019-1027.	2.4	10

#	Article	IF	Citations
235	Sarcoidosis and Cancer Risk. Chest, 2015, 147, 778-791.	0.4	122
236	New Treatments for Idiopathic Pulmonary Fibrosis: â€˜Die Another Day' if Diagnosed Early?. Respiration, 2015, 90, 352-352.	1.2	9
237	Morphine or Oxycodone for Cancer-Related Pain? A Randomized, Open-Label, Controlled Trial. Journal of Pain and Symptom Management, 2015, 49, 161-172.	0.6	59
238	Management of Scleroderma-Associated Pulmonary Involvement. Current Treatment Options in Rheumatology, 2015, 1, 51-67.	0.6	0
239	Pharmacological treatment of idiopathic pulmonary fibrosis: an update. Drug Discovery Today, 2015, 20, 514-524.	3.2	26
240	Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) â€” Report from OMERACT CTD-ILD Working Group. Journal of Rheumatology, 2015, 42, 2168-2171.	1.0	142
241	Palliative care for patients with advanced fibrotic lung disease: a randomised controlled phase II and feasibility trial of a community case conference intervention. Thorax, 2015, 70, 830-839.	2.7	97
242	An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2015, 192, e3-e19.	2.5	1,521
243	Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study. Lancet Respiratory Medicine,the, 2015, 3, 462-472.	5.2	252
244	Combination therapy in idiopathic pulmonary fibrosis: the way ahead will be hard. European Respiratory Journal, 2015, 45, 1208-1210.	3.1	11
245	A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials. European Respiratory Journal, 2015, 46, 243-249.	3.1	48
246	Severe Sarcoidosis. Clinics in Chest Medicine, 2015, 36, 715-726.	0.8	27
247	Smoking and interstitial lung diseases. European Respiratory Review, 2015, 24, 428-435.	3.0	56
248	CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab. European Respiratory Journal, 2015, 46, 1740-1750.	3.1	97
249	An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. European Respiratory Journal, 2015, 46, 976-987.	3.1	803
250	Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction. European Respiratory Journal, 2015, 46, 1370-1377.	3.1	129
251	Pulmonary Vasospasm in Systemic Sclerosis: Noninvasive Techniques for Detection. Pulmonary Circulation, 2015, 5, 498-505.	0.8	2
252	Challenges in IPF diagnosis, current management and future perspectives. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2015, 32 Suppl 1, 28-35.	0.2	7

#	Article	IF	Citations
253	Cyclical caspofungin for chronic pulmonary aspergillosis in sarcoidosis. Thorax, 2014, 69, 287-288.	2.7	28
254	Recurrent pneumothoraces in a 17-year-old man with mixed connective tissue disease. Thorax, 2014, 69, 685-686.	2.7	2
255	Quadriceps strength and endurance in fibrotic idiopathic interstitial pneumonia. Respirology, 2014, 19, 138-143.	1.3	47
256	Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants. Thorax, 2014, 69, 216-222.	2.7	176
257	Mycobacterium avium complex infection in nonâ€cystic fibrosis bronchiectasis. Respirology, 2014, 19, 714-722.	1.3	59
258	Pulmonary vascular limitation to exercise and survival in idiopathic pulmonary fibrosis. Respirology, 2014, 19, 269-275.	1.3	26
259	Prediction of Pulmonary Complications and Longâ€Term Survival in Systemic Sclerosis. Arthritis and Rheumatology, 2014, 66, 1625-1635.	2.9	354
260	Morphologic Predictors of a Microbiological Yield in Patients With a Tree-in-Bud Pattern on Computed Tomography. Journal of Thoracic Imaging, 2014, 29, 240-245.	0.8	4
261	Treatment strategies for idiopathic interstitial pneumonias. Current Opinion in Pulmonary Medicine, 2014, 20, 442-448.	1.2	19
262	Early diagnosis of IPF: time for a primary-care case-finding initiative?. Lancet Respiratory Medicine,the, 2014, 2, e1.	5.2	15
263	Interstitial Lung Disease in Systemic Sclerosis. Seminars in Respiratory and Critical Care Medicine, 2014, 35, 213-221.	0.8	53
264	Rituximab in severe, treatmentâ€refractory interstitial lung disease. Respirology, 2014, 19, 353-359.	1.3	217
265	Imaging aspects of the diagnosis of sarcoidosis. European Radiology, 2014, 24, 807-816.	2.3	42
266	Combination therapy: the future of management for idiopathic pulmonary fibrosis?. Lancet Respiratory Medicine,the, 2014, 2, 933-942.	5.2	128
267	Smoking-related idiopathic interstitial pneumonia. European Respiratory Journal, 2014, 44, 594-602.	3.1	36
268	The Role of Bacteria in the Pathogenesis and Progression of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 906-913.	2.5	453
269	Interstitial lung disease in systemic sclerosis. Presse Medicale, 2014, 43, e329-e343.	0.8	48
270	Interstitial lung disease in connective tissue diseaseâ€”mechanisms and management. Nature Reviews Rheumatology, 2014, 10, 728-739.	3.5	160

#	Article	IF	Citations
271	Pulmonary function, CT and echocardiographic abnormalities in sickle cell disease. Thorax, 2014, 69, 746-751.	2.7	31
272	Bosentan in Pulmonary Hypertension Associated with Fibrotic Idiopathic Interstitial Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 208-217.	2.5	177
273	An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study. Lancet Respiratory Medicine,the, 2014, 2, 123-130.	5.2	178
274	Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trial. Lancet Respiratory Medicine,the, 2014, 2, 277-284.	5.2	162
275	The Prognostic Value of the GAP Model In Chronic Interstitial Lung Disease. Chest, 2014, 145, 672-674.	0.4	10
276	Elevated Pulmonary Arterial Systolic Pressure (PASP) in Patients With Sarcoidosis: Prevalence and Risk Factors. Chest, 2014, 145, 244A.	0.4	0
277	Increased Spatial QRS-T Angle in First-Diagnosed Sarcoidosis Patients as a Marker of Cardiac Involvement. Chest, 2014, 145, 86A.	0.4	0
278	BNP Can Be an All-Cause Mortality Predictor in Sarcoidosis. Chest, 2014, 145, 253A.	0.4	0
279	Accuracy of Individual Variables in the Monitoring of Long-term Change in Pulmonary Sarcoidosis as Judged by Serial High-Resolution CT Scan Data. Chest, 2014, 145, 101-107.	0.4	38
280	Predicting Pulmonary Fibrosis Disease Course From Past Trends in Pulmonary Function. Chest, 2014, 145, 579-585.	0.4	95
281	A Biomarker Panel (Bioscore) Incorporating Monocytic Surface and Soluble TREM-1 Has High Discriminative Value for Ventilator-Associated Pneumonia: A Prospective Observational Study. PLoS ONE, 2014, 9, e109686.	1.1	36
282	A Combined Pulmonary Function and Emphysema Score Prognostic Index for Staging in Chronic Obstructive Pulmonary Disease. PLoS ONE, 2014, 9, e111109.	1.1	8
283	The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2014, 31, 19-27.	0.2	273
284	Treatment of sarcoidosis-associated pulmonary hypertension: A single centre retrospective experience using targeted therapies. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2014, 31, 82-90.	0.2	31
285	Pulmonary Hypertension Due to Left Heart Diseases. Journal of the American College of Cardiology, 2013, 62, D100-D108.	1.2	541
286	Serum Interleukin 6 Is Predictive of Early Functional Decline and Mortality in Interstitial Lung Disease Associated with Systemic Sclerosis. Journal of Rheumatology, 2013, 40, 435-446.	1.0	226
287	Pulmonary Hypertension in Chronic Lung Diseases. Journal of the American College of Cardiology, 2013, 62, D109-D116.	1.2	518
288	An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 733-748.	2.5	3,134

#	Article	IF	Citations
289	The evolving pharmacotherapy of pulmonary fibrosis. Expert Opinion on Pharmacotherapy, 2013, 14, 79-89.	0.9	23
290	Elevated Pulmonary Arterial Systolic Pressure in Patients with Sarcoidosis: Prevalence and Risk Factors. Lung, 2013, 191, 61-67.	1.4	37
291	Chronic hypersensitivity pneumonitis in the setting of definite IPF: does the current study undermine IPF guideline recommendations?. Lancet Respiratory Medicine,the, 2013, 1, 664-665.	5.2	4
292	Tobacco industry lobbyists and their health-care clients. Lancet, The, 2013, 381, 445.	6.3	3
293	Idiopathic Pulmonary Fibrosis Pathogenesis and Novel Approaches to Immunomodulation. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 677-679.	2.5	9
294	Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nature Genetics, 2013, 45, 613-620.	9.4	667
295	Novel use of rituximab in hypersensitivity pneumonitis refractory to conventional treatment. Thorax, 2013, 68, 780-781.	2.7	52
296	Interventions to improve symptoms and quality of life of patients with fibrotic interstitial lung disease: a systematic review of the literature. Thorax, 2013, 68, 867-879.	2.7	86
297	â€˜I wish I knew more ...â€™ the end-of-life planning and information needs for end-stage fibrotic interstitial lung disease: views of patients, carers and health professionals: TableÂ1. BMJ Supportive and Palliative Care, 2013, 3, 84-90.	0.8	71
298	The development and validation of the King's Sarcoidosis Questionnaire for the assessment of health status. Thorax, 2013, 68, 57-65.	2.7	92
299	The pathogenesis of pulmonary fibrosis: a moving target. European Respiratory Journal, 2013, 41, 1207-1218.	3.1	252
300	Forced vital capacity as a primary end point in idiopathic pulmonary fibrosis treatment trials: making a silk purse from a sow's ear. Thorax, 2013, 68, 309-310.	2.7	54
301	Managing diagnostic procedures in idiopathic pulmonary fibrosis. European Respiratory Review, 2013, 22, 158-162.	3.0	44
302	Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax, 2013, 68, 436-441.	2.7	193
303	Unclassified or unclassifiable interstitial lung disease: confusing or helpful disease category?: Table 1â€“. European Respiratory Journal, 2013, 42, 576-579.	3.1	24
304	A rapidly growing lung mass with air crescent formation. Thorax, 2013, 68, 394-395.	2.7	5
305	Acute Exacerbations of Idiopathic Pulmonary Fibrosis. Respiration, 2013, 86, 265-274.	1.2	43
306	Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan. Annals of Internal Medicine, 2013, 158, 641.	2.0	437

#	Article	IF	Citations
307	The palliative care needs for fibrotic interstitial lung disease: A qualitative study of patients, informal caregivers and health professionals. Palliative Medicine, 2013, 27, 869-876.	1.3	131
308	Smokingâ€related emphysema is associated with idiopathic pulmonary fibrosis and rheumatoid lung. Respirology, 2013, 18, 1191-1196.	1.3	51
309	Palliative care for people with non-malignant lung disease: Summary of current evidence and future direction. Palliative Medicine, 2013, 27, 811-816.	1.3	74
310	Clinical Relevance of Plasma Prostaglandin F2Î± Metabolite Concentrations in Patients with Idiopathic Pulmonary Fibrosis. PLoS ONE, 2013, 8, e66017.	1.1	21
311	Image Quality of Computed Tomographic Pulmonary Angiography for Suspected Pulmonary Embolus in Patients With Diffuse Interstitial Lung Disease. Journal of Thoracic Imaging, 2012, 27, 156-163.	0.8	2
312	The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire. Thorax, 2012, 67, 804-810.	2.7	180
313	Evidence-based Recommendations in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 5-7.	2.5	9
314	Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. European Respiratory Journal, 2012, 40, 641-648.	3.1	123
315	Pleuroparenchymal fibroelastosis: a spectrum of histopathological and imaging phenotypes. European Respiratory Journal, 2012, 40, 377-385.	3.1	335
316	Effect of Aging on Lung Structure In Vivo. Journal of Thoracic Imaging, 2012, 27, 366-371.	0.8	42
317	Diffuse Cystic Lung Disease of Unexplained Cause With Coexistent Small Airway Disease. American Journal of Surgical Pathology, 2012, 36, 228-234.	2.1	31
318	Azithromycin in bronchiectasis: when should it be used?. Lancet, The, 2012, 380, 627-629.	6.3	11
319	Diagnostic approach to interstitial lung disease. Current Respiratory Care Reports, 2012, 1, 199-207.	0.6	5
320	Hot of the breath: Mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good. Thorax, 2012, 67, 938-940.	2.7	71
321	Chronic Lung Disease in Adolescents With Delayed Diagnosis of Vertically Acquired HIV Infection. Clinical Infectious Diseases, 2012, 55, 145-152.	2.9	95
322	Morphometric analysis of intralobular, interlobular and pleural lymphatics in normal human lung. Journal of Anatomy, 2012, 220, 396-404.	0.9	31
323	Pulmonary capillary haemangiomatosis â€“ An unusual cause of hypoxia. Respiratory Medicine Case Reports, 2012, 7, 12-14.	0.2	3
324	Sarcoidosis and Tuberculosis Cytokine Profiles: Indistinguishable in Bronchoalveolar Lavage but Different in Blood. PLoS ONE, 2012, 7, e38083.	1.1	31

#	Article	IF	Citations
325	Chronic hypersensitivity pneumonitis: high resolution computed tomography patterns and pulmonary function indices as prognostic determinants. European Radiology, 2012, 22, 1672-1679.	2.3	157
326	Specialist Palliative Care is More Than Drugs: A Retrospective Study of ILD Patients. Lung, 2012, 190, 215-220.	1.4	94
327	Pulmonary function vascular index predicts prognosis in idiopathic interstitial pneumonia. Respirology, 2012, 17, 674-680.	1.3	23
328	Pulmonary Hypertension in Patients With Bronchiectasis: Prognostic Significance of CT Signs. American Journal of Roentgenology, 2011, 196, 1300-1304.	1.0	49
329	An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 788-824.	2.5	6,033
330	Method for Minimizing Observer Variation for the Quantitation of High-Resolution Computed Tomographic Signs of Lung Disease. Journal of Computer Assisted Tomography, 2011, 35, 596-601.	0.5	15
331	Idiopathic pulmonary fibrosisâ€related pulmonary hypertension; an exercising diagnosis?. Respirology, 2011, 16, 381-383.	1.3	2
332	Fibrotic idiopathic interstitial pneumonias: HRCT findings that predict mortality. European Radiology, 2011, 21, 1586-1593.	2.3	123
333	Improving the detection of pulmonary hypertension in systemic sclerosis using pulmonary function tests. Arthritis and Rheumatism, 2011, 63, 3531-3539.	6.7	37
334	CT Detection of Pulmonary Hypertension in Interstitial Lung Disease: The Glass Is Half Full. Radiology, 2011, 260, 628-631.	3.6	1
335	Baseline Values and Short Serial Change. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 395-397.	2.5	2
336	Forced Vital Capacity in Patients with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 1382-1389.	2.5	390
337	If it was good enough for Aristotle..... Thorax, 2011, 66, 183-1184.	2.7	3
338	An Essential Role for Resident Fibroblasts in Experimental Lung Fibrosis Is Defined by Lineage-Specific Deletion of High-Affinity Type II Transforming Growth Factor Î² Receptor. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 249-261.	2.5	103
339	Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design. Current Rheumatology Reviews, 2010, 6, 138-144.	0.4	28
340	Gastroesophageal Reflux Incites Interstitial Lung Disease in Systemic Sclerosis: Clinical, Radiologic, Histopathologic, and Treatment Evidence. Seminars in Arthritis and Rheumatism, 2010, 40, 241-249.	1.6	124
341	Prognostic factors in rapidly progressive interstitial pneumonia. Respirology, 2010, 15, 257-264.	1.3	16
342	Year in review 2009: Interstitial lung diseases, acute injury, sleep, physiology, imaging and bronchoscopic intervention. Respirology, 2010, 15, 172-181.	1.3	1

#	Article	IF	Citations
343	Diffuse alveolar damage in idiopathic pulmonary fibrosis: Does aetiology matter?. Respirology, 2010, 15, 873-875.	1.3	10
344	Alveolar proteinosis with hypersensitivity pneumonitis: A new clinical phenotype. Respirology, 2010, 15, 1197-1202.	1.3	14
345	The use of sildenafil to treat pulmonary hypertension associated with interstitial lung disease. Respirology, 2010, 15, 1226-1232.	1.3	38
346	Fibrotic idiopathic interstitial pneumonias: Mortality is linked to a decline in gas transfer. Respirology, 2010, 15, 1233-1243.	1.3	20
347	Sarcoidosis HLA class II genotyping distinguishes differences of clinical phenotype across ethnic groups. Human Molecular Genetics, 2010, 19, 4100-4111.	1.4	121
348	Non-invasive assessment of pulmonary blood flow using an inert gas rebreathing device in fibrotic lung disease. Thorax, 2010, 65, 341-345.	2.7	12
349	New pharmacological strategies for the treatment of pulmonary fibrosis. Therapeutic Advances in Respiratory Disease, 2010, 4, 353-366.	1.0	17
350	Detection of Pulmonary Hypertension with Multidetector CT and Echocardiography Alone and in Combination. Radiology, 2010, 254, 609-616.	3.6	176
351	Assessing Pulmonary Disease and Response to Therapy: Which Test?. Seminars in Respiratory and Critical Care Medicine, 2010, 31, 409-418.	0.8	51
352	Biopsy-proved Idiopathic Pulmonary Fibrosis: Spectrum of Nondiagnostic Thin-Section CT Diagnoses. Radiology, 2010, 254, 957-964.	3.6	128
353	Non-Langerhans Histiocytosis Mimicking Sarcoidosis on High-resolution Computed Tomography. Journal of Thoracic Imaging, 2010, 25, W133-W135.	0.8	2
354	The Art and Science of Diagnosing Interstitial Lung Diseases. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 974-975.	2.5	9
355	Autologous Hematopoietic Stem Cell Transplant in Systemic Sclerosis: Quantitative High Resolution Computed Tomography of the Chest Scoring. Journal of Rheumatology, 2009, 36, 1460-1463.	1.0	38
356	Lung Morphology in the Elderly: Comparative CT Study of Subjects over 75 Years Old versus Those under 55 Years Old. Radiology, 2009, 251, 566-573.	3.6	165
357	The frequency of neuroendocrine cell hyperplasia in patients with pulmonary neuroendocrine tumours and nonâ€neuroendocrine cell carcinomas. Histopathology, 2009, 55, 332-337.	1.6	40
358	Road ahead to respiratory health: Experts chart future research directions. Respirology, 2009, 14, 625-636.	1.3	12
359	Lost in translation; from animal models of pulmonary fibrosis to human disease. Respirology, 2009, 14, 915-916.	1.3	13
360	Non-specific interstitial pneumonia in cigarette smokers: a CT study. European Radiology, 2009, 19, 1679-1685.	2.3	56

#	Article	IF	Citations
361	Fibroblastâ€specific perturbation of transforming growth factor Î² signaling provides insight into potential pathogenic mechanisms of sclerodermaâ€associated lung fibrosis: Exaggerated response to alveolar epithelial injury in a novel mouse model. Arthritis and Rheumatism, 2008, 58, 1175-1188.	6.7	51
362	PET scanning of macrophages in patients with scleroderma fibrosing alveolitis. Nuclear Medicine and Biology, 2008, 35, 901-909.	0.3	17
363	Different angiogenic CXC chemokine levels in bronchoalveolar lavage fluid after interferon gamma-1b therapy in idiopathic pulmonary fibrosis patients. Pulmonary Pharmacology and Therapeutics, 2008, 21, 840-844.	1.1	15
364	Pulmonary Complications of Connective Tissue Diseases. Clinics in Chest Medicine, 2008, 29, 149-164.	0.8	37
365	Nonspecific Interstitial Pneumonia and Idiopathic Pulmonary Fibrosis: Changes in Pattern and Distribution of Disease over Time. Radiology, 2008, 247, 251-259.	3.6	186
366	Interstitial Lung Disease in Systemic Sclerosis. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 1248-1254.	2.5	930
367	Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 190-194.	2.5	161
368	Update in Diffuse Parenchymal Lung Disease 2007. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 580-584.	2.5	16
369	The Effect of Diffuse Pulmonary Fibrosis on the Reliability of CT Signs of Pulmonary Hypertension. Radiology, 2008, 249, 1042-1049.	3.6	139
370	Idiopathic Nonspecific Interstitial Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 1338-1347.	2.5	528
371	Challenges in pulmonary fibrosis {middle dot} 4: Smoking-induced diffuse interstitial lung diseases. Thorax, 2007, 62, 904-910.	2.7	68
372	Pulmonary Function Tests in Connective Tissue Disease. Seminars in Respiratory and Critical Care Medicine, 2007, 28, 379-388.	0.8	33
373	Update in Diffuse Parenchymal Lung Disease 2006. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 655-660.	2.5	21
374	Pulmonary Complications of Connective Tissue Disease. Seminars in Respiratory and Critical Care Medicine, 2007, 28, 367-368.	0.8	0
375	Asbestos-induced and Smoking-related Disease: Apportioning Pulmonary Function Deficit by Using Thin-Section CT. Radiology, 2007, 242, 258-266.	3.6	35
376	Daily Cyclophosphamide for Scleroderma. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 952-953.	2.5	29
377	Idiopathic Interstitial Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 1054-1060.	2.5	241
378	Computed Tomographic Imaging in Connective Tissue Diseases. Seminars in Respiratory and Critical Care Medicine, 2007, 28, 389-397.	0.8	43

#	Article	IF	Citations
379	Imaging in Sarcoidosis. Seminars in Respiratory and Critical Care Medicine, 2007, 28, 102-120.	0.8	143
380	Acute Exacerbations of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 636-643.	2.5	996
381	Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: an under-recognised spectrum of disease. Thorax, 2007, 62, 248-252.	2.7	227
382	Association between Heat Shock Protein 70/Hom Genetic Polymorphisms and Uveitis in Patients with Sarcoidosis. , 2007, 48, 3019.		50
383	Peripheral-type benzodiazepine receptors in bronchoalveolar lavage cells of patients with interstitial lung disease. Nuclear Medicine and Biology, 2007, 34, 553-558.	0.3	11
384	Bronchoalveolar lavage cellular profiles in patients with systemic sclerosisâ€“associated interstitial lung disease are not predictive of disease progression. Arthritis and Rheumatism, 2007, 56, 2005-2012.	6.7	155
385	Quantification of emphysema: a composite physiologic index derived from CT estimation of disease extent. European Radiology, 2007, 17, 911-918.	2.3	46
386	Nasal Levels of Nitric Oxide as an Outcome Variable in Allergic Upper Respiratory Tract Disease: Influence of Atopy and Hayfever on nNO. American Journal of Rhinology & Allergy, 2006, 20, 425-429.	2.3	22
387	Classification of Interstitial Pneumonias. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 141-142.	2.5	7
388	No pain relief from morphine?. Supportive Care in Cancer, 2006, 14, 56-64.	1.0	116
389	A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis and Rheumatism, 2006, 54, 3962-3970.	6.7	632
390	Interstitial Lung Disease: Effects of Thin-Section CT on Clinical Decision Making. Radiology, 2006, 238, 725-733.	3.6	45
391	Patient-specific bronchoscopy visualization through BRDF estimation and disocclusion correction. IEEE Transactions on Medical Imaging, 2006, 25, 503-513.	5.4	26
392	REPRODUCIBILITY OF RELATIVE REGIONAL ASSESSMENT USING THE VIBRATION RESPONSE IMAGING DEVICE. Chest, 2006, 130, 169S.	0.4	0
393	C-C Chemokine Receptor 5 Gene Variants in Relation to Lung Disease in Sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 721-728.	2.5	62
394	Functional Impairment in Emphysema: Contribution of Airway Abnormalities and Distribution of Parenchymal Disease. American Journal of Roentgenology, 2005, 185, 1509-1515.	1.0	92
395	Six-Minute Walk, Maximal Exercise Tests. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 1150-1157.	2.5	253
396	Interlobular Septal Thickening in Idiopathic Bronchiectasis: A Thin-Section CT Study of 94 Patients. Radiology, 2005, 237, 1091-1096.	3.6	14

#	Article	IF	Citations
397	Prostacyclin for pulmonary hypertension in adults. The Cochrane Library, 2005, , CD002994.	1.5	29
398	Lung Function and High Resolution Computed Tomography in Sickle Cell Disease.. Blood, 2005, 106, 3182-3182.	0.6	0
399	Organizing Pneumonia: Perilobular Pattern at Thin-Section CT. Radiology, 2004, 232, 757-761.	3.6	182
400	Prognostic Implications of Histologic Patterns in Multiple Surgical Lung Biopsies From Patients With Idiopathic Interstitial Pneumonias. Chest, 2004, 125, 522-526.	0.4	214
401	CT Features of Lung Disease in Patients with Systemic Sclerosis: Comparison with Idiopathic Pulmonary Fibrosis and Nonspecific Interstitial Pneumonia. Radiology, 2004, 232, 560-567.	3.6	338
402	Histopathologic Diagnosis in Diffuse Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 828-829.	2.5	37
403	Respiratory bronchiolitis associated with interstitial lung disease and desquamative interstitial pneumonia. Clinics in Chest Medicine, 2004, 25, 717-726.	0.8	44
404	Invasive Pulmonary Aspergillosis Is Not a Contraindication to Reduced-Intensity Conditioned Allogeneic Haematopoietic Stem Cell Transplantation (RIC allo-HSCT).. Blood, 2004, 104, 1831-1831.	0.6	0
405	Traction bronchiectasis in cryptogenic fibrosing alveolitis: associated computed tomographic features and physiological significance. European Radiology, 2003, 13, 1801-1808.	2.3	33
406	Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 962-969.	2.5	571
407	Terminal Diffuse Alveolar Damage in Relation to Interstitial Pneumonias. American Journal of Clinical Pathology, 2003, 119, 709-714.	0.4	117
408	High-Resolution Computed Tomography in the Diagnosis of Diffuse Lung Disease: A Clinical Perspective. Seminars in Respiratory and Critical Care Medicine, 2003, 24, 347-356.	0.8	21
409	Interstitial Vascularity in Fibrosing Alveolitis. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 438-443.	2.5	172
410	Respiratory Bronchiolitis-Associated Interstitial Lung Disease. Seminars in Respiratory and Critical Care Medicine, 2003, 24, 585-594.	0.8	37
411	Fibrotic Idiopathic Interstitial Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 531-537.	2.5	544
412	C-C Chemokine Receptor 2 and Sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 1162-1166.	2.5	103
413	Asbestosis and Idiopathic Pulmonary Fibrosis: Comparison of Thin-Section CT Features. Radiology, 2003, 229, 731-736.	3.6	124
414	Evaluation and management of alveolitis and interstitial lung disease in scleroderma. Current Opinion in Rheumatology, 2003, 15, 748-755.	2.0	86

#	Article	IF	Citations
415	Drug treatments of the future in fibrotic lung disease. , 2003, , 336-360.		0
416	Terminal diffuse alveolar damage in relation to interstitial pneumonias. An autopsy study. American Journal of Clinical Pathology, 2003, 119, 709-14.	0.4	56
417	Thin-Section CT in Obstructive Pulmonary Disease: Discriminatory Value. Radiology, 2002, 223, 812-819.	3.6	89
418	Asymmetric ARDS Following Pulmonary Resection: CT Findingsâ€"Initial Observations. Radiology, 2002, 223, 468-473.	3.6	65
419	Histopathologic Subsets of Fibrosing Alveolitis in Patients with Systemic Sclerosis and Their Relationship to Outcome. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 1581-1586.	2.5	736
420	The Relationship between Individual Histologic Features and Disease Progression in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 173-177.	2.5	262
421	Successful Treatment of Endogenous Lipoid Pneumonia due to Niemannâ€"Pick Type B Disease with Whole-Lung Lavage. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 128-131.	2.5	75
422	Increased Frequency of the Uncommon Tumor Necrosis Factor â^' 857T Allele in British and Dutch Patients with Sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 1119-1124.	2.5	133
423	Loss of FEV1 in cystic fibrosis: correlation with HRCT features. European Radiology, 2002, 12, 2229-2235.	2.3	33
424	Lung fibrosis: new classifications and therapy. Current Opinion in Rheumatology, 2001, 13, 500-504.	2.0	23
425	Functional Consequences of Pleural Disease Evaluated with Chest Radiography and CT. Radiology, 2001, 220, 237-243.	3.6	75
426	Spirometric lung volumes in the adult Pacific Islander population: Comparison with predicted values in a European population. Respirology, 2001, 6, 247-253.	1.3	12
427	Nonspecific Interstitial Pneumoniaâ€"Nobody Said It's Perfect. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 1553-1554.	2.5	38
428	Cryptogenic Organizing Pneumonia. Seminars in Respiratory and Critical Care Medicine, 2001, 22, 449-460.	0.8	47
429	Nonspecific Interstitial Pneumonia and Usual Interstitial Pneumonia: Comparative Appearances at and Diagnostic Accuracy of Thin-Section CT. Radiology, 2001, 221, 600-605.	3.6	305
430	Acute Respiratory Distress Syndrome Caused by Pulmonary and Extrapulmonary Injury: A Comparative CT Study. Radiology, 2001, 218, 689-693.	3.6	118
431	Allergic Bronchopulmonary Aspergillosis in the Asthma Clinic. Chest, 2000, 118, 66-72.	0.4	108
432	Distribution of novel polymorphisms of the interleukin-8 and CXC receptor 1 and 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis. Arthritis and Rheumatism, 2000, 43, 1633-1640.	6.7	102

#	Article	IF	Citations
433	Nonspecific Interstitial Pneumonia: Variable Appearance at High-Resolution Chest CT. Radiology, 2000, 217, 701-705.	3.6	232
434	Evaluation of Patients Undergoing Lung Volume Reduction Surgery: Ancillary Information Available from Computed Tomography. Clinical Radiology, 2000, 55, 45-50.	0.5	27
435	Increased nitric oxide production in the respiratory tract in asymptomatic Pacific Islanders: An association with skin prick reactivity to house dust mite. Journal of Allergy and Clinical Immunology, 2000, 105, 895-899.	1.5	58
436	Distribution of novel polymorphisms of the interleukin-8 and CXC receptor 1 and 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis. , 2000, 43, 1633.		3
437	Nitrofurantoin-Induced Lung Disease: Two Cases Demonstrating Resolution of Apparently Irreversible CT Abnormalities. Journal of Computer Assisted Tomography, 2000, 24, 259-261.	0.5	45
438	Mechanism of mosaic attenuation of the lungs on computed tomography in induced bronchospasm. Journal of Applied Physiology, 1999, 86, 701-708.	1.2	29
439	Follicular Bronchiolitis: Thin-Section CT and Histologic Findings. Radiology, 1999, 212, 637-642.	3.6	212
440	Acute Respiratory Distress Syndrome: CT Abnormalities at Long-term Follow-up. Radiology, 1999, 210, 29-35.	3.6	205
441	Normal Adult Values, Diurnal Variation, and Repeatability of Nasal Nitric Oxide Measurement. American Journal of Rhinology & Allergy, 1999, 13, 401-406.	2.3	38
442	A CT Sign of Chronic Pulmonary Arterial Hypertension: The Ratio of Main Pulmonary Artery to Aortic Diameter. Journal of Thoracic Imaging, 1999, 14, 270-278.	0.8	362
443	A Comparison of Methods for Enhancing the Detection of Areas of Decreased Attenuation on CT Caused by Airways Disease. Journal of Computer Assisted Tomography, 1999, 23, 385-389.	0.5	37
444	Computed tomographic imaging of bronchiolar disorders. Current Opinion in Pulmonary Medicine, 1998, 4, 85-92.	1.2	12
445	CT Evaluation of Fibrosing Alveolitisâ€"Applications and Insights. Journal of Thoracic Imaging, 1996, 11, 231-249.	0.8	21
446	Bronchiectasis: A neglected cause of respiratory morbidity and mortality. Respirology, 1996, 1, 221-225.	1.3	45
447	P065 <break /> A multicentre evaluation of inter-multidisciplinary team agreement for diagnosis in diffuse lung disease. QJM - Monthly Journal of the Association of Physicians, 0, , .	0.2	0